| | | 68897 | | 13.02.2024 | | Luye Pharma Switzerland AG | | | | | | | 12.02.2029 | | | | | | | | | | 01.99. | | |
| | Seq.-No. | Product | Description | Galenic form | ATC-classification | |
|---|
| 01 | Rivasur zweimal wöchentlich 4,6 mg/24 Stunden | Transdermales Pflaster | Transdermal patch ((Transdermales Pflaster): Rivastigminum 25.92 mg) + Transdermal patch () | N06DA03 | | | 02 | Rivasur zweimal wöchentlich 9,5 mg/24 Stunden | Transdermales Pflaster | Transdermal patch ((Transdermales Pflaster): Rivastigminum 51.84 mg) + Transdermal patch () | N06DA03 | |
|
|
